Acrylamide-encapsulated glucose oxidase inhibits breast cancer cell viability

Rrustemi T., Geyik O. G., Ozkaya A. B., Öztürk T. K., Yüce Z., Kılınç A.

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, cilt.45, sa.6, ss.811-816, 2020 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 45 Sayı: 6
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1515/tjb-2020-0247
  • Dergi Adı: TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.811-816
  • Anahtar Kelimeler: biocompatibility, cancer therapy, glucose oxidase, MCF-7, single enzyme nanoparticle, starving-like therapy, therapeutic enzyme, NANOPARTICLES, ASPARAGINASE
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objectives: Cancer cells modulate metabolic pathways to ensure continuity of energy, macromolecules and redoxhomeostasis. Although these vulnerabilities are often targeted individually, targeting all with an enzyme may prove a novel approach. However, therapeutic enzymes are prone to proteolytic degradation and neutralizing antibodies leading to a reduced half-life and effectiveness. We hypothesized that glucose oxidase (GOX) enzyme that catalyzes oxidation of glucose and production of hydrogen peroxide, may hit all these targets by depleting glucose; crippling anabolic pathways and producing reactive oxygen species (ROS); unbalancing redox homeostasis.